Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 12Glioblastoma 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasm Metastasis 1Medulloblastoma 1Inflammatory Breast Neoplasms 1Her2 Positive Metastatic Breast Cancer 1Head and Neck Neoplasms 1HER2 Positive Metastatic Breast Cancer 1Gliosarcoma 1Familial ependymoma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Brain Neoplasms 1Astrocytoma 1

Interventions

Trastuzumab 3Paclitaxel 3Docetaxel 3Taxes 2Cyclophosphamide 2trastuzumab biosimilar HLX02 1tipifarnib 1romidepsin 1pertuzumab 1pegfilgrastim 1onvansertib 1neratinib 1grapiprant 1eribulin 1caficrestat 1Peripheral Blood Stem Cell Transplantation 1PF-05280014 1Ontruzant 1Ogivri 1Mesna 1Lapatinib 1Filgrastim 1Epirubicin 1Doxorubicin 1Depsipeptides 1Carboplatin 1Capecitabine 1Albumin-Bound Paclitaxel 12C4 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Inflammatory Breast Neoplasms × Lapatinib × Clear all
NCT00450892 2016-07-07

Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 1/2 Completed
129 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡